REFERENCES
- Ashraf V. V., Taly A. B., Veerendrakumar M., Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurologica Scandinavica 2006; 114(2)119–123
- Balasa B., Deng C., Lee J., Bradley L. M., Dalton D. K., Christadoss P., Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. Journal of Experimental Medicine 1997; 186(3)385–391
- Deng C., Goluszko E., Tuzun E., Yang H., Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. Journal of Immunology 2002; 169(2)1077–1083
- Girndt M. Humoral immune responses in uremia and the role of IL-10. Blood Purif 2002; 20(5)485–488
- Goluszko E., Deng C., Poussin M. A., Christadoss P. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. Journal of Neuroimmunology 2002; 122(1–2)85–93
- Hohlfeld R., Conti-Tronconi B., Kalies I., Bertrams J., Toyka K. V. Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in myasthenia gravis. Journal of Immunology 1985; 135(4)2393–2399
- Poussin M. A., Goluszko E., David C. S., Franco J. U., Christadoss P. HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production. Journal of Autoimmun 2001; 17(3)175–180
- Poussin M. A., Goluszko E., Franco J. U., Christadoss P. Role of IL-5 during primary and secondary immune response to acetylcholine receptor. Journal of Neuroimmunology 2002; 125(1–2)51–58
- Poussin M. A., Goluszko E., Hughes T. K., Duchicella S. I., Christadoss P. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. Journal of Neuroimmunology 2000; 111(1–2)152–160
- Spellberg B., Edwards J. E., Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32(1)76–102
- Tuzun E., Meriggioli M. N., Rowin J., Yang H, Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. Journal of Autoimmun 2005; 24(3)261–268
- Tuzun E., Scott B. G., Goluszko E., Higgs S., Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. Journal of Immunology 2003; 171(7)3847–3854
- Utsugisawa K., Nagane Y., Obara D., Kondoh R., Yonezawa H., Tohgi H. Interleukin-2 production by peripheral blood mononuclear cells from patients with myasthenia gravis. European Neurology 2003; 49(3)160–163
- Zhang G. X., Navikas V., Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 1997; 20(5)543–551